Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects

Current Pharmaceutical Design

Volumn 18, Issue 2, 2012, Pages 209-219

  Weber, Martin S ^a   Menge, Til ^b   Lehmann Horn, Klaus ^a   Kronsbein, Helena C ^a   Zettl, Uwe ^c   Sellner, Johann ^a,d   Hemmer, Bernhard ^a   Stüve, Olaf ^e,f,g  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Department of Orthopedic Surgery   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d PARACELSUS MEDICAL UNIVERSITY   (Austria)

^e VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

B cells; Immunomodulation; Immunosuppression; Multiple sclerosis; Progressive multifocal leucoencephalopathy; T cells; Therapy

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; CD20 ANTIBODY; CLADRIBINE; FINGOLIMOD; FLUDARABINE; GADOLINIUM; GLATIRAMER; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; LAQUINIMOD; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; OCRELIZUMAB; OFATUMUMAB; PLACEBO; RAZOXANE; RITUXIMAB; ROQUINIMEX; STEROID;

ACUTE GRANULOCYTIC LEUKEMIA; ALLERGIC ENCEPHALITIS; ALOPECIA; ANEMIA; ANTIINFLAMMATORY ACTIVITY; APHTHOUS MOUTH ULCER; ATRIOVENTRICULAR BLOCK; ATTENUATION; AUTOIMMUNITY; B LYMPHOCYTE; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; BRADYCARDIA; BUDD CHIARI SYNDROME; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CHORIOCARCINOMA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COMMON COLD; COMPLEMENT DEPENDENT CYTOTOXICITY; CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; DEPRESSION; DISABILITY; DISEASE CONTROL; DRUG EFFICACY; DRUG FORMULATION; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GENE EXPRESSION; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FAILURE; HEMATOLOGIC MALIGNANCY; HEMOLYTIC ANEMIA; HERPES SIMPLEX; HERPES ZOSTER; HOT FLUSH; HUMAN; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFECTION; INFERTILITY; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; LATENT TUBERCULOSIS; LEUKOPENIA; LIVER DYSFUNCTION; LIVER ENZYME BLOOD LEVEL; LIVER INJURY; LIVER TOXICITY; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTOPENIA; MACROPHAGE; MEASLES; MELANOMA; MENINGITIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NAUSEA; NEOPLASM; NEUROIMAGING; NEUROLOGIC DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CARCINOMA; PANCREAS CARCINOMA; PANCYTOPENIA; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PYOGENIC GRANULOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR DOWN REGULATION; RECOMMENDED DRUG DOSE; RELAPSE; RESPIRATORY TRACT INFECTION; RETINA MACULA EDEMA; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SINUSITIS; SPIROCHETAL GINGIVITIS; SUBCUTANEOUS LIPODYSTROPHY; T LYMPHOCYTE; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; UTERUS MYOMA;

ANIMALS; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; T-LYMPHOCYTES;

EID: 84856489659     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799040501     Document Type: Review

References (126)

1. van Boxel-Dezaire AH, Rani MR, Stark GR. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity. 2006 Sep; 25(3): 361-72.
2. Taniguchi T, Takaoka A. The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol. 2002 Feb; 14(1): 111-6.
3. Then Bergh F, Dayyani F, Ziegler-Heitbrock L. Impact of type-Iinterferon on monocyte subsets and their differentiation to dendritic cells. An in vivo and ex vivo study in multiple sclerosis patients treated with interferon-beta. J Neuroimmunol. 2004 Jan; 146(1-2): 176-88.
4. Vandenbark AA, Huan J, Agotsch M, La Tocha D, Goelz S, Offner H, et al. Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol. 2009 Oct 30; 215(1-2): 125-8.
5. Noronha A, Toscas A, Jensen MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol. 1993 Jul; 46(1-2): 145-53.
6. Bernal F, Elias B, Hartung HP, Kieseier BC. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients. Mult Scler. 2009 Jun; 15(6): 721-7.
7. Oliver BJ, Kohli E, Kasper LH. Interferon therapy in relapsingremitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials. J Neurol Sci. 2011 Mar 15; 302(1-2): 96-105.
8. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet. 1998 Nov 7; 352(9139): 1491-7.
9. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology. 2003 Jan 14; 60(1): 44-51.
10. Kappos L, Weinshenker B, Pozzilli C, Thompson AJ, Dahlke F, Beckmann K, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology. 2004 Nov 23; 63(10): 1779-87.
11. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology. 2001 Jun 12; 56(11): 1496-504.
12. Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol. 1971 Aug; 1(4): 242-8.
13. Teitelbaum D, Webb C, Bree M, Meshorer A, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer. Clin Immunol Immunopathol. 1974 Nov; 3(2): 256-62.
14. Lisak RP, Zweiman B, Blanchard N, Rorke LB. Effect of treatment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE). J Neurol Sci. 1983 Dec; 62(1-3): 281-93.
15. Teitelbaum D, Fridkis-Hareli M, Arnon R, Sela M. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J Neuroimmunol. 1996 Feb; 64(2): 209-17.
16. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology. 1995; 45: 1268-76.
17. Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008 Oct; 7(10): 903-14.
18. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, et al. 250 mug or 500 mug interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009 Oct; 8(10): 889-97.
19. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest. 2000 Apr; 105(7): 967-76.
20. Neuhaus O, Farina C, Yassouridis A, Wiendl H, Then Bergh F, Dose T, et al. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci U S A. 2000; 97(13): 7452-7.
21. Vieira PL, Heystek HC, Wormmeester J, Wierenga EA, Kapsenberg ML. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol. 2003 May 1; 170(9): 4483-8.
22. Kantengwa S, Weber MS, Juillard C, Benkhoucha M, Fellay B, Zamvil SS, et al. Inhibition of naive Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis. J Neuroimmunol. 2007 Apr; 185(1-2): 123-9.
23. Hong J, Li N, Zhang X, Zheng B, Zhang JZ. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci U S A. 2005 May 3; 102(18): 6449-54.
24. Weber MS, Prod'homme T, Youssef S, Dunn SE, Rundle CD, Lee L, et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med. 2007 Aug; 13(8): 935-43.
25. Karandikar NJ, Crawford MP, Yan X, Ratts RB, Brenchley JM, Ambrozak DR, et al. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest. 2002 Mar; 109(5): 641-9.
26. Teitelbaum D, Milo R, Arnon R, Sela M. Synthetic copolymer 1 inhibits human T cell lines specific for myelin basic protein. Proc Natl Acad Sci U S A. 1992 Jan 1; 89(1): 137-41.
27. Gran B, Tranquill LR, Chen M, Bielekova B, Zhou W, Dhib-Jalbut S, et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology. 2000 Dec 12; 55(11): 1704-14.
28. Weber MS, Starck M, Wagenpfeil S, Meinl E, Hohlfeld R, Farina C. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain. 2004 Jun; 127(Pt 6): 1370-8.
29. Kim HJ, Ifergan I, Antel JP, Seguin R, Duddy M, Lapierre Y, et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol. 2004 Jun 1; 172(11): 7144-53.
30. Stasiolek M, Bayas A, Kruse N, Wieczarkowiecz A, Toyka KV, Gold R, et al. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain. 2006 May; 129(Pt 5): 1293-305.
31. Stuve O, Youssef S, Weber MS, Nessler S, von Budingen HC, Hemmer B, et al. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest. 2006 Apr; 116(4): 1037-44.
32. Burger D, Molnarfi N, Weber MS, Brandt KJ, Benkhoucha M, Gruaz L, et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci U S A. 2009 Mar 17; 106(11): 4355-9.
33. Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R, Zamvil SS, et al. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs. 2011 May 1; 25(5): 401-14.
34. Tan IL, Lycklamaa Nijeholt GJ, Polman CH, Ader HJ, Barkhof F. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. Mult Scler. 2000 Apr; 6(2): 99-104.
35. Wegner C, Stadelmann C, Pfortner R, Raymond E, Feigelson S, Alon R, et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010 Oct 8; 227(1-2): 133-43.
36. Bruck W, Wegner C. Insight into the mechanism of laquinimod action. J Neurol Sci. 2011 Mar 21.
37. Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology. 2005 Mar 22; 64(6): 987-91.
38. Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008 Jun 21; 371(9630): 2085-92.
39. Thielmann HW, Popanda O, Gersbach H, Gilberg F. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts. Carcinogenesis. 1993 Nov; 14(11): 2341-51.
40. Fisher GR, Patterson LH. DNA strand breakage by peroxidaseactivated mitoxantrone. J Pharm Pharmacol. 1991 Jan; 43(1): 65-8.
41. Neuhaus O, Wiendl H, Kieseier BC, Archelos JJ, Hemmer B, Stuve O, et al. Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro. Journal of neuroimmunology. 2005 Nov; 168(1-2): 128-37.
42. Chan A, Weilbach FX, Toyka KV, Gold R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol. 2005 Jan; 139(1): 152-8.
43. Vogelgesang A, Rosenberg S, Skrzipek S, Broker BM, Dressel A. Mitoxantrone treatment in multiple sclerosis induces TH2-type cytokines. Acta Neurol Scand. 2010 Oct; 122(4): 237-43.
44. Kopadze T, Dehmel T, Hartung HP, Stuve O, Kieseier BC. Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis. Archives of neurology. 2006 Nov; 63(11): 1572-8.
45. Watson CM, Davison AN, Baker D, O'Neill JK, Turk JL. Suppression of demyelination by mitoxantrone. International journal of immunopharmacology. 1991; 13(7): 923-30.
46. Fox EJ. Mechanism of action of mitoxantrone. Neurology. 2004 Dec 28; 63(12 Suppl 6): S15-8.
47. Millefiorini E, Gasperini C, Pozzilli C, D'Andrea F, Bastianello S, Trojano M, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol. 1997 Mar; 244(3): 153-9.
48. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002 Dec 21-28; 360(9350): 2018-25.
49. Krapf H, Morrissey SP, Zenker O, Zwingers T, Gonsette R, Hartung HP. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology. 2005 Sep 13; 65(5): 690-5.
50. van de Wyngaert FA, Beguin C, D'Hooghe MB, Dooms G, Lissoir F, Carton H, et al. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta neurologica Belgica. 2001 Dec; 101(4): 210-6.
51. Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry. 1997 Feb; 62(2): 112-8.
52. Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA. Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting. Clin Neurol Neurosurg. 2010 Dec; 112(10): 876-82.
53. Kornek B, Bernert G, Rostasy K, Mlczoch E, Feucht M, Prayer D, et al. Long-term follow-up of pediatric patients treated with mitoxantrone for multiple sclerosis. Neuropediatrics. 2011 Feb; 42(1): 7-12.
54. Kuntz NL, Chabas D, Weinstock-Guttman B, Chitnis T, Yeh EA, Krupp L, et al. Treatment of multiple sclerosis in children and adolescents. Expert Opin Pharmacother. 2010 Mar; 11(4): 505-20.
55. Langer-Gould A, Moses HH, Murray TJ. Strategies for managing the side effects of treatments for multiple sclerosis. Neurology. 2004 Dec 14; 63(11 Suppl 5): S35-41.
56. Kingwell E, Koch M, Leung B, Isserow S, Geddes J, Rieckmann P, et al. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology. 2010 Jun 1; 74(22): 1822-6.
57. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010 May 4; 74(18): 1463-70.
58. Bernitsas E, Wei W, Mikol DD. Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. Ann Neurol. 2006 Jan; 59(1): 206-9.
59. Pascual AM, Tellez N, Bosca I, Mallada J, Belenguer A, Abellan I, et al. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler. 2009 Nov; 15(11): 1303-10.
60. Le Page E, Leray E, Edan G. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study. Mult Scler. 2011 Jul; 17(7): 867-75.
61. Zecca C, Petrini L, Limoni C, Staedler C, Gobbi C. Tolerability and acceptance of prolonged low/delayed mitoxantrone regimens in patients with worsening multiple sclerosis. European neurology. 2011; 65(1): 40-5.
62. Arnold DL, Campagnolo D, Panitch H, Bar-Or A, Dunn J, Freedman MS, et al. Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. Journal of Neurology. 2008 Oct; 255(10): 1473-8.
63. Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2008 Jun; 14(5): 663-70.
64. Edan G, Comi G, Le Page E, Leray E, Rocca MA, Filippi M. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J Neurol Neurosurg Psychiatry. 2011 Mar 24.
65. Costello F, Stüve O, Weber MS, Zamvil SS, Frohman E. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice. Curr Opin Neurol 2007; 20(3): 281-5.
66. Cotte S, von Ahsen N, Kruse N, Huber B, Winkelmann A, Zettl UK, et al. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain. 2009 Sep; 132(Pt 9): 2517-30.
67. Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet. 1997 Feb; 32(2): 120-31.
68. Beutler E. New chemotherapeutic agent: 2-chlorodeoxyadenosine. Semin Hematol. 1994 Jan; 31(1): 40-5.
69. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sorensen P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4; 362(5): 416-26.
70. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002 Jun 14; 277(24): 21453-7.
71. Webb M, Tham CS, Lin FF, Lariosa-Willingham K, Yu N, Hale J, et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol. 2004 Aug; 153(1-2): 108-21.
72. Kataoka H, Sugahara K, Shimano K, Teshima K, Koyama M, Fukunari A, et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol. 2005 Dec; 2(6): 439-48.
73. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006 Sep 14; 355(11): 1124-40.
74. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4; 362(5): 402-15.
75. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4; 362(5): 387-401.
76. Kowarik MC, Pellkofer HL, Cepok S, Korn T, Kumpfel T, Buck D, et al. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology. 2011 Apr 5; 76(14): 1214-21.
77. Hemmer B, Frohman E, Hartung HP, Stuve O. Central nervous system infections-a potential complication of systemic immunotherapy. Curr Opin Neurol. 2006 Jun; 19(3): 271-6.
78. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992 Mar 5; 356(6364): 63-6.
79. Leger OJ, Yednock TA, Tanner L, Horner HC, Hines DK, Keen S, et al. Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies. 1997; 8(1): 3-16.
80. Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP, et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology. 1999 Aug 11; 53(3): 466-72.
81. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003 Jan 2; 348(1): 15-23.
82. O'Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, et al. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology. 2004 Jun 8; 62(11): 2038-43.
83. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2; 354(9): 899-910.
84. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2; 354(9): 911-23.
85. Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009 Mar; 8(3): 254-60.
86. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005 Jul 28; 353(4): 369-74.
87. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005 Jul 28; 353(4): 375-81.
88. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005 Jul 28; 353(4): 362-8.
89. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010 Apr; 9(4): 438-46.
90. Hellwig K, Gold R. Progressive multifocal leukoencephalopathy and natalizumab. J Neurol. 2011 Jun 7.
91. Vermersch P, Kappos L, Gold R, Foley JF, Olsson T, Cadavid D, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology. 2011 May 17; 76(20): 1697-704.
92. Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010 Sep; 68(3): 295-303.
93. Ricciardiello L, Laghi L, Ramamirtham P, Chang CL, Chang DK, Randolph AE, et al. JC virus DNA sequences are frequently present in the human upper and lower gastrointestinal tract. Gastroenterology. 2000 Nov; 119(5): 1228-35.
94. Perez-Liz G, Del Valle L, Gentilella A, Croul S, Khalili K. Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol. 2008 Oct; 64(4): 379-87.
95. Warnke C, Menge T, Hartung HP, Racke MK, Cravens PD, Bennett JL, et al. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol. 2010 Aug; 67(8): 923-30.
96. Stuve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006 May; 59(5): 743-7.
97. Stuve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, et al. Altered CD4+/CD8+ T cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol. 2006 Oct; 63(10): 1383-7.
98. del Pilar Martin M, Cravens PD, Winger R, Frohman EM, Racke MK, Eagar TN, et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol. 2008 Dec; 65(12): 1596-603.
99. Lindberg RL, Achtnichts L, Hoffmann F, Kuhle J, Kappos L. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol. 2008 Feb; 194(1-2): 153-64.
100. Zohren F, Toutzaris D, Klarner V, Hartung HP, Kieseier B, Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood. 2008 Apr 1; 111(7): 3893-5.
101. Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006 Jan; 253(1): 98-108.
102. Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008 Oct 23; 359(17): 1786-801.
103. Lim SH, Hale G, Marcus RE, Waldmann H, Baglin TP. CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura. Br J Haematol. 1993 Jul; 84(3): 542-4.
104. Watts RA, Isaacs JD, Hale G, Hazleman BL, Waldmann H. CAMPATH-1H in inflammatory arthritis. Clin Exp Rheumatol. 1993 Mar-Apr; 11 Suppl 8: S165-7.
105. Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 1999 Nov 13; 354(9191): 1691-5.
106. Coles A, Deans J, Compston A. Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clin Neurol Neurosurg. 2004 Jun; 106(3): 270-4.
107. Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain. 2010 Aug; 133(Pt 8): 2232-47.
108. Jones JL, Coles AJ. Spotlight on alemtuzumab. Int MS J. 2009 Sep; 16(3): 77-81.
109. Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009 Oct; 128(2): 260-70.
110. Turner M, LaMorte, M., Stockman, A., Roberts, B., Kaplan, J., Siders, W. Analysis of Innate Immune Cells Following Alemtuzumab Treatment in Human CD52 Transgenic Mice. P02201, presented at the AAN 2011. 2011.
111. Brinar V, on Behalf of the CAMMS223 Study Group. Alemtuzumab and Thyroid Autoimmunity in Relapsing-Remitting Multiple Sclerosis Patients in CAMMS223. P03242, presented at the AAN 2011. 2011.
112. Watanabe M, Amino N, Hochito K, Watanabe K, Kuma K, Iwatani Y. Opposite changes in serum soluble CD8 in patients at the active stages of Graves' and Hashimoto's diseases. Thyroid. 1997 Oct; 7(5): 743-7.
113. Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis. 2008 Sep; 67(9): 1322-7.
114. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 Feb 14; 358(7): 676-88.
115. Broadley SA, Deans J, Sawcer SJ, Clayton D, Compston DA. Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain. 2000 Jun; 123 (Pt 6): 1102-11.
116. Hsiao LT, Liu JH, Yen CC, Wang WS, Fan FS, Chiou TJ, et al. Relapse of Graves' disease after successful allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001 Dec; 28(12): 1151-3.
117. Gilquin J, Viard JP, Jubault V, Sert C, Kazatchkine MD. Delayed occurrence of Graves' disease after immune restoration with HAART. Highly active antiretroviral therapy. Lancet. 1998 Dec 12; 352(9144): 1907-8.
118. Daikeler T, Tyndall A. Autoimmunity following haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol. 2007 Jun; 20(2): 349-60.
119. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebocontrolled multicenter trial. Ann Neurol. 2009 Oct; 66(4): 460-71.
120. Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011 Oct 31.
121. Martin Mdel P, Cravens PD, Winger R, Kieseier BC, Cepok S, Eagar TN, et al. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol. 2009 Aug; 66(8): 1016-20.
122. Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A, Ghorayeb C, et al. Abnormal B cell cytokine responses a trigger of T cellmediated disease in MS? Ann Neurol. 2010 Apr; 67(4): 452-61.
123. Weber MS, Prod'homme T, Patarroyo JC, Molnarfi N, Karnezis T, Lehmann-Horn K, et al. B cell activation influences T cell polarization and outcome of anti-CD20 B cell depletion in central nervous system autoimmunity. Ann Neurol. 2010 Sep; 68(3): 369-83.
124. Lehmann-Horn K, Schleich E, Hertzenberg D, Hapfelmeier A, Kumpfel T, von Bubnoff N, et al. Anti-CD20 B cell depletion enhances monocyte reactivity in neuroimmunological disorders. J Neuroinflammation. 2011; 8: 146.
125. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009 May 14; 113(20): 4834-40.
126. Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, et al. Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis. Arch Neurol. 2011 May 9.